JP2012523417A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523417A5
JP2012523417A5 JP2012504760A JP2012504760A JP2012523417A5 JP 2012523417 A5 JP2012523417 A5 JP 2012523417A5 JP 2012504760 A JP2012504760 A JP 2012504760A JP 2012504760 A JP2012504760 A JP 2012504760A JP 2012523417 A5 JP2012523417 A5 JP 2012523417A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
lcvr
hcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012504760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012523417A (ja
JP5759977B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/030039 external-priority patent/WO2010117980A1/en
Publication of JP2012523417A publication Critical patent/JP2012523417A/ja
Publication of JP2012523417A5 publication Critical patent/JP2012523417A5/ja
Application granted granted Critical
Publication of JP5759977B2 publication Critical patent/JP5759977B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012504760A 2009-04-10 2010-04-06 Dkk−1抗体 Active JP5759977B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16841109P 2009-04-10 2009-04-10
US61/168,411 2009-04-10
PCT/US2010/030039 WO2010117980A1 (en) 2009-04-10 2010-04-06 Dkk-1 antibodies

Publications (3)

Publication Number Publication Date
JP2012523417A JP2012523417A (ja) 2012-10-04
JP2012523417A5 true JP2012523417A5 (https=) 2013-05-16
JP5759977B2 JP5759977B2 (ja) 2015-08-05

Family

ID=42199718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012504760A Active JP5759977B2 (ja) 2009-04-10 2010-04-06 Dkk−1抗体

Country Status (30)

Country Link
US (1) US8148498B2 (https=)
EP (3) EP2417158B9 (https=)
JP (1) JP5759977B2 (https=)
KR (3) KR20110124364A (https=)
CN (1) CN102388065B (https=)
AR (1) AR075989A1 (https=)
AU (1) AU2010234611B2 (https=)
BR (1) BRPI1014157B1 (https=)
CA (1) CA2758252C (https=)
CY (3) CY1119399T1 (https=)
DK (3) DK3514173T3 (https=)
EA (1) EA021401B1 (https=)
ES (3) ES2644244T3 (https=)
HR (3) HRP20171400T1 (https=)
HU (3) HUE043904T2 (https=)
IL (1) IL214845A (https=)
LT (3) LT2417158T (https=)
ME (2) ME03378B (https=)
MX (1) MX2011010707A (https=)
NZ (1) NZ595011A (https=)
PL (3) PL2417158T3 (https=)
PT (3) PT3514173T (https=)
RS (3) RS58612B1 (https=)
SG (1) SG175244A1 (https=)
SI (3) SI2417158T1 (https=)
TR (1) TR201907261T4 (https=)
TW (1) TWI546079B (https=)
UA (1) UA103916C2 (https=)
WO (1) WO2010117980A1 (https=)
ZA (1) ZA201107256B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596274A (en) 2009-05-12 2013-11-29 Pfizer Blocking anti-dkk-1 antibodies and their uses
AU2013359419B2 (en) 2012-12-10 2018-03-15 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
US10584174B2 (en) 2015-05-18 2020-03-10 Eli Lilly And Company Anti-Dkk-1-anti-RANKL bispecific antibody compounds
KR20180054639A (ko) * 2015-08-28 2018-05-24 알렉터 엘엘씨 항-siglec-7 항체 및 이의 사용 방법
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
CA3041325A1 (en) * 2016-10-26 2018-05-03 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN119841953A (zh) 2018-06-08 2025-04-18 艾利妥 抗siglec-7抗体及其使用方法
KR20210044783A (ko) * 2018-07-11 2021-04-23 모멘타 파머슈티컬스 인코포레이티드 CTLA-4 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
CA3151228A1 (en) * 2019-09-19 2021-03-25 Leap Therapeutics, Inc. Use of dkk-1 inhibitors for treating cancer
EP4061419A1 (en) * 2019-11-22 2022-09-28 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors
KR102494042B1 (ko) * 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
CA3206789A1 (en) * 2021-02-05 2022-08-11 Gregory A. Demopulos Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
WO2023143444A1 (zh) * 2022-01-28 2023-08-03 上海君实生物医药科技股份有限公司 抗dkk1抗体、其药物组合物及用途
IL318268A (en) 2022-07-12 2025-03-01 Leap Therapeutics Inc Combined treatment
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69842225D1 (de) 1997-04-16 2011-05-26 Millennium Pharm Inc Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
JP2005512508A (ja) 2001-05-17 2005-05-12 ゲノム セラピューティックス コーポレーション Dkk媒介性相互作用を変調する試薬および方法
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
MXPA04004378A (es) 2001-11-07 2004-09-10 Univ Arkansas Diagnostico, prognosis e identificacion de objetivos terapeuticos potenciales de mieloma multiple basado en el perfilado de expresion de genes.
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
JP2007525953A (ja) 2003-06-06 2007-09-13 ワイス 骨リモデリングを調節する物質を同定するための方法および材料、ならびにそれによって同定された物質
WO2006015373A2 (en) 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CA2677356A1 (en) * 2007-02-08 2008-08-14 Zhiqiang An Antibodies specific for dkk-1
EP2427490A1 (en) * 2009-05-07 2012-03-14 Novartis AG Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both

Similar Documents

Publication Publication Date Title
JP2012523417A5 (https=)
ME02798B (me) Protutijela protiv dkk-1"
HRP20171992T1 (hr) Protutijela protiv cgrp
JP2013542194A5 (https=)
JP2015514110A5 (https=)
SI3042917T1 (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
JP2020500538A5 (https=)
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
RU2019112029A (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
JP2013529183A5 (https=)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
HRP20191678T1 (hr) Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena
JP2013542191A5 (https=)
NZ603972A (en) Anti-fgfr2 antibodies
JP2020502198A5 (https=)
JP2023055904A5 (https=)
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
RU2015110981A (ru) Комбинации и их применение
RU2018105846A (ru) Комбинация антагониста pd-1 с ингибитором egfr
JP2015535828A5 (https=)
TN2012000416A1 (en) Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
NZ592436A (en) Treatment with anti-alpha2 integrin antibodies
NZ723369A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema